Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peanut allergy immunotherapy - DBV Technologies

Next Previous
Drug Profile

Peanut allergy immunotherapy - DBV Technologies

Alternative Names: Current Viaskin peanut patch; cVP; DBV 712; EPIT®; Modified Viaskin peanut patch; mVP; Viaskin Peanut; Viaskin™ Peanut

Latest Information Update: 13 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DBV Technologies
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Peanut hypersensitivity

Most Recent Events

  • 13 May 2026 Phase-III clinical trials in Peanut hypersensitivity (In infants, In children) in Spain (Topical) (NCT07003919)
  • 30 Apr 2026 DBV Technologies plan phase II THRIVE trial for Peanut hypersensitivity (In infants)
  • 24 Mar 2026 DBV Technologies initiates the phase III COMFORT Toddlers trial for Peanut hypersensitivity (In infants, In children) in Australia, Canada, France, Ireland, Netherlands, United Kingdom (Topical) (NCT07003919)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top